Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium
Abstract Aggressiveness of carcinomas is linked with tumor recruitment of adipose stromal cells (ASC), which is increased in obesity. ASC promote cancer through molecular pathways not fully understood. Here, we demonstrate that epithelial–mesenchymal transition (EMT) in prostate tumors is promoted by obesity and suppressed upon pharmacological ASC depletion in HiMyc mice, a spontaneous genetic model of prostate cancer. CXCL12 expression in tumors was associated with ASC recruitment and localized to stromal cells expressing platelet-derived growth factor receptors Pdgfra and Pdgfrb. The role of this chemokine secreted by stromal cells in cancer progression was further investigated by using tissue-specific knockout models. ASC deletion of CXCL12 gene in the Pdgfr + lineages suppressed tumor growth and EMT, indicating stroma as the key source of CXCL12. Clinical sample analysis revealed that CXCL12 expression by peritumoral adipose stroma is increased in obesity, and that the correlating increase in Pdgfr/CXCL12 expression in the tumor is linked with decreased survival of patients with prostate carcinoma. Our study establishes ASC as the source of CXCL12 driving tumor aggressiveness and outlines an approach to treatment of carcinoma progression..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
npj Precision Oncology - 5(2021), 1, Seite 10 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fei Su [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
|---|
| doi: |
10.1038/s41698-021-00160-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ059693797 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ059693797 | ||
| 003 | DE-627 | ||
| 005 | 20240414111414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41698-021-00160-9 |2 doi | |
| 035 | |a (DE-627)DOAJ059693797 | ||
| 035 | |a (DE-599)DOAJ278639b602984827ab52b214507bb321 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Fei Su |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progression of prostate carcinoma is promoted by adipose stromal cell-secreted CXCL12 signaling in prostate epithelium |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Aggressiveness of carcinomas is linked with tumor recruitment of adipose stromal cells (ASC), which is increased in obesity. ASC promote cancer through molecular pathways not fully understood. Here, we demonstrate that epithelial–mesenchymal transition (EMT) in prostate tumors is promoted by obesity and suppressed upon pharmacological ASC depletion in HiMyc mice, a spontaneous genetic model of prostate cancer. CXCL12 expression in tumors was associated with ASC recruitment and localized to stromal cells expressing platelet-derived growth factor receptors Pdgfra and Pdgfrb. The role of this chemokine secreted by stromal cells in cancer progression was further investigated by using tissue-specific knockout models. ASC deletion of CXCL12 gene in the Pdgfr + lineages suppressed tumor growth and EMT, indicating stroma as the key source of CXCL12. Clinical sample analysis revealed that CXCL12 expression by peritumoral adipose stroma is increased in obesity, and that the correlating increase in Pdgfr/CXCL12 expression in the tumor is linked with decreased survival of patients with prostate carcinoma. Our study establishes ASC as the source of CXCL12 driving tumor aggressiveness and outlines an approach to treatment of carcinoma progression. | ||
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Alexes C. Daquinag |e verfasserin |4 aut | |
| 700 | 0 | |a Songyeon Ahn |e verfasserin |4 aut | |
| 700 | 0 | |a Achinto Saha |e verfasserin |4 aut | |
| 700 | 0 | |a Yulin Dai |e verfasserin |4 aut | |
| 700 | 0 | |a Zhongming Zhao |e verfasserin |4 aut | |
| 700 | 0 | |a John DiGiovanni |e verfasserin |4 aut | |
| 700 | 0 | |a Mikhail G. Kolonin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t npj Precision Oncology |d Nature Portfolio, 2017 |g 5(2021), 1, Seite 10 |w (DE-627)DOAJ000133973 |x 2397768X |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2021 |g number:1 |g pages:10 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41698-021-00160-9 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/278639b602984827ab52b214507bb321 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41698-021-00160-9 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2397-768X |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2021 |e 1 |h 10 | ||